Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a$25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company’s preliminary estimates, and potentially into the third ...